Antiviral Activity of Recombinant Mouse β-defensin 3 against Influenza a Virus in vitro and in vivo
Authors:
Open Access
- 1 June 2012
- journal article
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 22 (6) , 255-262
Abstract
Background: Influenza causes significant morbidity and mortality. Mammalian β-defensins are small peptides of about 4.5–6 kDa in mass and are effectors of the innate immune response with potent antimicrobial activity. In this paper, we focused on the anti-influenza A activity of the recombinant mouse β-defensin 3 (rMBD-3) in vivo and in vitro. Methods: The rMBD-3 peptide was added to Madin-Darby canine kidney (MDCK) cells at different stages of influenza A virus (IAV) A/PR/8/34 (H1N1) infection and its virus inhibitory properties were determined. Mice were infected with IAV and treated with rMBD-3 peptide from 12 h post-infection. The effect of rMBD-3 peptide was determined by pulmonary viral load, pathology and mortality. In addition, the expression of interleukin ( IL) -12, interferon ( IFN)-γ and tumour necrosis factor ( TNF)-α genes in mice with or without rMBD-3 treatment was determined by semi-quantitative reverse transcriptase PCR. Results: rMBD-3 was shown to protect MDCK cells against IAV infection and had a major role in inhibition of adsorption and uptake by cells infected with IAV. Following the addition of 100 μg/ml rMBD-3 to MDCK cells medium, approximately 80% of cells were protected from infection in vitro. rMBD-3 given by tail vein injection (10 mg/kg/day) was the most effective method to improve the survival rate of the mice. Treatment with rMBD-3 was found to up-regulate IFN-γ and IL-12 gene expression, but reduced expression of the TNF-α gene. Conclusions: These results demonstrate that rMBD-3 possesses anti-influenza virus activity both in vivo and in vitro that might be of therapeutic use.Keywords
This publication has 25 references indexed in Scilit:
- Insight into the Mechanisms of Adenovirus Capsid Disassembly from Studies of Defensin NeutralizationPLOS Pathogens, 2010
- Targeting pandemic influenza: a primer on influenza antivirals and drug resistanceJournal of Antimicrobial Chemotherapy, 2010
- Cyclic and Acyclic Defensins Inhibit Human Immunodeficiency Virus Type-1 Replication by Different MechanismsPLOS ONE, 2010
- Recombinant mouse beta-defensin 2 inhibits infection by influenza A virus by blocking its entryArchives of Virology, 2010
- Retrocyclin 2: a new therapy against avian influenza H5N1 virus in vivo and vitroBiotechnology Letters, 2009
- Rhesus Theta-Defensin Prevents Death in a Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Pulmonary DiseaseJournal of Virology, 2009
- Expression of mouse beta-defensin-3 in MDCK cells and its anti-influenza-virus activityArchives of Virology, 2009
- Anti-Human Immunodeficiency Virus Type 1 Activities of Antimicrobial Peptides Derived from Human and Bovine CathelicidinsAntimicrobial Agents and Chemotherapy, 2008
- Inhibition of Herpes Simplex Virus Type 1 Infection by Cationic β-PeptidesAntimicrobial Agents and Chemotherapy, 2008
- The guinea pig as a transmission model for human influenza virusesProceedings of the National Academy of Sciences, 2006